Design
NF1, Noonan syndrome
NOONAN SYNDROME
The SynCoRAS study is a monocentre, randomized, double-blind, parallel-group, placebo-controlled, cross-over clinical trial phase IIa. The trial design is shown in Figs. Graphical flowchart of the study design for NS (experiment I and II). In experiment I, patients with Noonan syndrome first receive lamotrigine (LTG) or placebo (PLC) with a minimum pause of 7 days and maximum of 60 days. In experiment II, lovastatin (LOV) or PLC with a minimum pause of 7 days and maximum 60 days. Between experiments, there will be a pause of at least 14 daysGraphical flow-chart of the study design for NF1 (experiment III). In experiment III, patients with NF1 first receive lamotrigine (LTG) or placebo (PLC) with a minimum pause of 7 days and maximum of 60 days